An observational study in Sepsis, Septic Shock and Infections, sponsored by National University Hospital, Singapore. Recruiting at 1 site in Singapore. Open to participants aged 21 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by National University Hospital, Singapore · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this prospective observational study is to investigate if a point-of-care testing device using microfluidics can evaluate the biophysical characteristics of white blood cells for the rapid diagnosis and prognosis of acute infection or sepsis.
Our main aim is to develop a rapid biophysical sparing assay protocol for the diagnosis and/or prognosis of acute infection and sepsis in the ED among patients with non-specific symptoms, by differentiating infection vs. non-infection in febrile cases, viral vs. bacterial cause of infection (if infection present) and low vs. high risk of sepsis with organ dysfunction.
Our primary aims are:
A total of 3 ml (slightly more than half teaspoon) of blood sample via intravenous cannulation in addition to clinically indicated full blood count will be collected from study participants and placed into EDTA vacutainer tubes. Automated aspiration of up to 100 µl of blood from the EDTA tube will be performed by the prototype and loaded onto the PDMS microfluidic device for the biophysical assay. The white blood cell biophysical properties (count, size, distribution and deformability) will be analyzed at various flow rates through the microfluidic system. Biophysical indices and characteristics will be recorded. Results will be blinded to attending clinicians.
Clinical charts will be reviewed and clinical progression of the patients charted and grouped into infective vs. no infection in febrile cases; viral vs. bacterial cause of infection (if infection present) and low vs. high risk of sepsis with organ dysfunction. The electronic medical records of subjects will be reviewed for inpatient admissions and up to 30 days from day of discharge from ED or hospital to follow up on outcomes.
1,079 studies on the registry are indexed under Shock, Septic; 232 are open to participants now.
This study's planned enrollment of 304 is above the median of 108 across 406 observational studies indexed under Shock, Septic.
Browse Shock, Septic studies →National University Hospital, Singapore is the lead sponsor of 455 studies on the registry; 100 are open to participants now.
Compared within Shock, Septic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Sepsis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Adult emergency department patients, aged 21 years old and above, in whom attending clinician suspects infection (including patients with unexplained fever or vague symptoms) OR those who have a clear and objective source of systemic infection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A total of 3 ml (slightly more than half teaspoon) of blood sample via intravenous cannulation in addition to clinically indicated full blood count will be collected from study participants and placed into EDTA vacutainer tubes. Automated aspiration of up to 100 µl of blood from the EDTA tube will be performed by the prototype and loaded onto the PDMS microfluidic device for the biophysical assay.
Diagnostic Test: Microfluidic device for assessment of biophysical properties of white blood cells
Point-of-care label-free immune profiling assay from 20 µL of unprocessed blood using unconventional L and Inverse-L shaped pillars of deterministic lateral displacement microfluidic technology to characterize immune cell size, deformability, distribution, and cell counts.
Infective vs. no infection in febrile cases
Sensitivity, specificity and accuracy of our diagnostic platform
Time frame: Up to 30 days
Viral vs. bacterial cause of infection (if infection present)
Sensitivity, specificity and accuracy of our diagnostic platform
Time frame: Up to 30 days
Low vs. high risk of sepsis with organ dysfunction
Sensitivity, specificity and accuracy of our diagnostic platform
Time frame: Up to 30 days
Started Jun 2026 (actual). Primary completion is estimated for May 2027, 10 months after the start.
Of 188 non-industry observational studies under Shock, Septic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 47. This study's planned 10 months is below that.
Counting every sponsor, half of 201 studies reached it within 25 months; a quarter within 12 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National University Hospital, Singapore →